Insight

Guillermo Villacampa: The safety and efficacy of ADCs with immunotherapy

Guillermo Villacampa/ vhio.net

Oct 20, 2024, 10:56

Guillermo Villacampa: The safety and efficacy of ADCs with immunotherapy

“Antibody-drug conjugate (ADCs) in combination with immunotherapy is emerging as a promising strategy. However, concerns arise regarding the safety.

In this work, we present a combined analysis evaluating the safety and efficacy of this combination.”

Guillermo Villacampa

Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis

Authors: Guillermo Villacampa, Pablo Cresta Morgado, Lorenzo Carità, Victor Navarro, Tomas Pascual and Rodrigo Dienstmann.

Guillermo Villacampa

ADC Antibody-drug conjugate (ADCs) cancer cancer awareness cancer care fight against cancer Global fight against cancer Guillermo Villacampa immunotherapy Lorenzo Carità OncoDaily Oncology Pablo Cresta Morgado Rodrigo Dienstmann Tomás Pascual VHIO Victor Navarro

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology